Skip to Main Content

Advertisement

Skip Nav Destination

EMA Assessing Gene Therapy for Sickle Cell Disease

December 30, 2021

The European Medicines Agency (EMA) accepted the autologous gene therapy, known as LentiGlobin BB305 Drug Product, for sickle cell disease (SCD) for its accelerated assessment.

With LentiGlobin BB305 Drug Product, a functioning hemoglobin (Hb) gene (an engineered ßA-T87Q-globin gene) is transported into a patient's hematopoietic stem cells ex vivo before being infused back into the patient's blood.

This drug product previously received breakthrough therapy designation from the U.S. Food and Drug Administration for treating transfusion-dependent beta-thalassemia.

Source: Bluebird Bio press release, September 27, 2016.

Advertisement

Connect with us:

CURRENT ISSUE
September 2022

Advertisement

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement